

Fax
received
10/17/03
-D. Lukton

CHOATE, HALL & STEWART
A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS
EXCHANGE PLACE
53 STATE STREET
BOSTON, MASSACHUSETTS 02109-2804
TELEPHONE (617) 248-5000 • FAX (617) 248-4000
www.CHOATE.COM

TRANSMITTAL SHEET

Number of pages being sent 13 (including this page)

DATE: October 17, 2003

Recipient	Company	Fax No.	Phone No.
1. Examiner D. Lukton	U.S. Patent and Trademark Office	1-703-746-0571	

FROM: C. Hunter Baker, M.D., Ph.D.

DIRECT DIAL: (617) 248-5215

REMARKS: U.S. Patent Application for "Multivalent Compound for Crosslinking Receptors and Uses Thereof" by Bachovchin
U.S.S.N.: 09/289,321; Filed: April 9, 1999
Attorney's Docket Number: 2002941-0053

TIME SENT: _____ **OPERATOR:** _____ **CLIENT NO.** 2002941-0053

Return by: Inter-office Mail _____ Hold for pick-up _____

THIS TRANSMITTAL IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS TRANSMITTAL IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE TRANSMITTAL TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY.
Received from <617 248 4000> at 10/17/03 2:04:44 PM [Eastern Daylight Time]

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			Applicant: Bachovchin		
			Filing Date: April 9, 1999	Group: 1653	
U. S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	* 4,318,904	Shaw <i>et al.</i>	March 9, 1982	424	177
	* 4,443,609	Oude Alink <i>et al.</i>	April 17, 1984	548	111
	* 4,499,082	Shenvi <i>et al.</i>	February 12, 1985	514	2
	* 4,582,821	Kettner <i>et al.</i>	April 15, 1986	514	18
	* 4,636,492	Kettner <i>et al.</i>	January 13, 1987	514	18
	* 4,644,055	Kettner <i>et al.</i>	February 17, 1987	530	330
	* 4,652,552	Kettner <i>et al.</i>	March 24, 1987	514	18
	* 4,935,493	Bachovchin <i>et al.</i>	June 19, 1990	530	331
	* 4,963,655	Kinder <i>et al.</i>	October 16, 1990	530	331
	* 5,093,477	Mölling <i>et al.</i>	March 3, 1992	530	328
	* 5,187,157	Kettner <i>et al.</i>	February 16, 1993	514	18
	* 5,215,926	Etchells, III <i>et al.</i>	June 1, 1993	436	501
	* 5,242,904	Kettner <i>et al.</i>	September 7, 1993	514	18
	* 5,250,720	Kettner <i>et al.</i>	October 5, 1993	558	288
	* 5,288,707	Metternich	February 22, 1994	514	19
	* 5,296,604	Hanko <i>et al.</i>	March 22, 1994	546	169
	* 5,329,028	Ashkenazi <i>et al.</i>	July 12, 1994	548	548
	* 5,378,624	Berenson <i>et al.</i>	January 3, 1995	435	239
	* 5,384,410	Kettner <i>et al.</i>	January 24, 1995	548	405
*	* 5,444,049	de Nanteuil <i>et al.</i>	August 22, 1995	514	18
	* 5,462,928	Bachovchin <i>et al.</i>	October 31, 1995	514	19

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
INFORMATION DISCLOSURE STATEMENT				Applicant: Bachovchin		
(Use several sheets if necessary)				Filing Date: April 9, 1999	Group: 1653	
	* 5,506,130	Peterson <i>et al.</i>		April 9, 1996	435	240.1
	* 5,527,923	Klinger <i>et al.</i>		June 18, 1996	548	570
	* 5,543,396	Powers <i>et al.</i>		August 6, 1996	514	19
	* 5,554,728	Basava <i>et al.</i>		September 10, 1996	530	327
	* 5,635,386	Passon <i>et al.</i>		June 3, 1997	435	372
	* 5,635,387	Fei <i>et al.</i>		June 3, 1997	435	378
	* 5,646,043	Emerson <i>et al.</i>		July 8, 1997	435	373

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	DD158109	Germany	29 December 1982		X
	DD270382A1	Germany	26 July 1989		X
	DD296075A5	Germany	21 November 1991		X
	EP 0356223A2	Europe	28 February 1990	X	
	EP 0371467A2	Europe	6 June 1990		X
	* EP 0420913B1	Europe	15 November 1995		
	* EP 0471651A2	Europe	19 February 1992		
	EP 0481311A2	Europe	22 April 1992		X
	EP 0615978A1	Europe	21 September 1994		X
	EP 0688788A1	Europe	27 December 1995		X
	* WO 89/03223	PCT	20 April 1989		
	* WO 91/16339	PCT	31 October 1991		
	* WO 91/17767	PCT	28 November 1991		

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT		Applicant: Bachovchin			
(Use several sheets if necessary)				Filing Date: April 9, 1999	Group: 1653
	* WO 92/12140	PCT	23 July 1992		
	* WO 92/17490	PCT	15 October 1992		
	* WO 93/02057	PCT	4 February 1993		
	* WO 93/05011	PCT	18 March 1993		
	* WO 93/08259	PCT	29 April 1993		
	* WO 93/10127	PCT	27 May 1993		
	* WO 93/16102	PCT	19 August 1993		
	* WO 94/03055	PCT	17 February 1994		
	* WO 94/09132	PCT	28 April 1994		
	* WO 94/20526	PCT	15 September 1994		
	* WO 94/25873	PCT	10 November 1994		
	* WO 94/28915	PCT	22 December 1994		
	* WO 94/29335	PCT	22 December 1994		
	* WO 95/11689	PCT	4 May 1995		
	WO 95/15309	PCT	6 June 1995		X
	* WO 95/15309	PCT	8 June 1995		
	* WO 95/12618	PCT	11 May 1995		
	* WO 95/29190	PCT	2 November 1995		
	* WO 95/29691	PCT	9 November 1995		
	* WO 95/34538	PCT	21 December 1995		
	* WO 96/40858	PCT	19 December 1996		
	* WO 96/40263	PCT	19 December 1996		
	WO 98/00439	PCT	8 January 1998		X
	WO 98/50046	PCT	12 November 1998		X
	WO 98/50066	PCT	12 November 1998		X

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin			
				Filing Date: April 9, 1999	Group: 1653
	WO 99/16854	PCT	8 April 1999	X	
Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Aguila, H.L., et al., "From Stem Cells To Lymphocytes: Biology and Transplantation", <i>Immun. Rev.</i> , 157:13-40, (1997) Ansorge, et al., "CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation", 127:140. * Austin, D.J., et al., "Proximity Versus Allostery: The Role of Regulated Protein Dimerization in Biology", <i>Chemistry & Biology</i> , 1:131-136, (1994) * Bachovchin, W.W., et al., "Inhibition Of IGA 1 Proteinases From Neisseria Gonorrhoeae And Hemophilus Influenzae By Peptide Prolyl Boronic Acids", <i>J. Biol. Chem.</i> , 265:3738-3743 (1990). * Bailey, P.D., "An Introduction To Peptide Chemistry", <i>Wiley Publishers</i> , 1-81, (1990) * Barton, R.W.J., et al., "Binding Of The T Cell Activation Monoclonal Antibody Tal To Dipeptidyl Peptidase IV", <i>J. Leukocyte Biology</i> , 48:291-296 (1990). Baugh, R., et al., "Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction", <i>Proteinases And Tumor Invasion</i> , 165:157-180 (1980). * Blumenstein, et al., "Synthetic Non-Peptide Inhibitors of HIV Protease" <i>Biochemical and Biophysical Research Communications</i> 163(2): 980-87, 1989. * Bodanszky, M., "Principles Of Peptide Synthesis", <i>Springer-Verlag</i> , 16: (1984) * Bodanszky, M., "The Practice Of Peptide Synthesis", <i>Springer-Verlag</i> , 21: (1984) * Bodanzky, M., "Peptide Chemistry, A Practical Textbook", <i>Springer-Verlag</i> , (1988) 1-9. * Boros, L.G., et al., "Fluoroolefin Peptide Isosteres-Tools For Controlling Peptide Conformations", <i>Tetrahedron Letters</i> , 35:6033-6036, (1994) * Brady, L., and Dodson, G., "Reflections On A Peptide", <i>Nature</i> , 368:692-693, (1994) * Brander, et al., "Heterogeneous T Cell Responses to β -Lactam-Modified Self-Structures Are Observed in Penicillin-Allergic Individuals" <i>J. Immunol.</i> 155 (5):2670-2678 (1995). * Brenchley, et al., "Towards Defining Antigens in Human Membranous Nephropathy" <i>Nephrology, Dialysis, Transplantation</i> 7 Suppl. 1: 21-24, (1992). Bristol, L.A., et al., "Characterization Of A Novel Rat Thymocyte Costimulating Antigen By The Monoclonal Antibody 1.3", <i>J. Immunol.</i> 148:332-338 (1992). * Bristol, L.A., et al., "Thymocyte Costimulating Antigen is CD26 (Dipeptidyl-Peptidase IV), Co-stimulation Of Granulocyte, Macrophage, T Lineage Cell Proliferation Via CD26," <i>J. Immunol.</i> 149:367-372 (1992). Bristol, et al., "Inhibition of CD26 Enzyme Activity with Pro-boropro Stimulates Rat Granulocyte/Macrophage Colony Formation and Thymocyte Proliferation In Vitro", <i>Blood</i> , 85(12): 3602-3609, 1995.				

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin	
		Filing Date: April 9, 1999	Group: 1653
<p>* Bungy, et al., "Mapping of T Cell Epitopes of the Major Fraction of Rye Grass Using Peripheral Blood Mononuclear Cells From Atopics and Non-Atopics. II. Isoallergen Clone 5A of <i>Lolium Perenne</i> Group I (<i>Lol p 1</i>)", <i>Eur. J. Immunol.</i>, 24 (9):2098-2103 (1994).</p> <p>* Chan, et al., "Archives of Ophthalmology" 113 (5):597-600 (1995).</p> <p>* Chazenblak, et al., "Human Organ-Specific Autoimmune Disease", Molecular Cloning and Expression of an Autoantibody Gene Repertoire For a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ, <i>J. Clinical Investigation</i> 92 (1):62-74 (1993).</p> <p>* Colowick, S., et al., "Methods In Enzymology", Pp. 220-225.</p> <p>* Cordes, E., et al., "Transition States For Hydrolysis Of Acetals, Ketals Glycosides, And Glycosylamines", Chapter 11, Pp. 429-465</p> <p>* Coutts, et al., "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P₂ Position of X_{as}-boroPro Dipeptides", <i>J. Med. Chem.</i>, 39: 2087-94, 1996.</p> <p>* Dang, N.H., et al., "Cell Surface Modulation of CD26 By Anti-1F7 Monoclonal Antibody: Analysis Of Surface Expression And Human T Cell Activation", <i>J. Immunol.</i>, 145:3963-3971 (1990).</p> <p>* Darcy, et al., "Protection of Mice and Nude Rats Against Toxolasmosis by A Multiple Antigenic Peptide Construction Derived From <i>Toxoplasma Gondii</i> P30 Antigen", <i>J. Immunol.</i> 149 (11):3636-3641 (1992).</p> <p>* Darmoul, D., et al. "Dipeptidyl Peptidase IV (CD26) Gene Expression in Enterocyte-like Colon Cancer Cell Lines HT-29 And Caco-2; Cloning Of The Complete Human Coding Sequence And Changes of Dipeptidyl Peptidase IV mRNA Levels During Cell Differentiation," <i>J. Biological Chemistry</i>, 267:2220-2228 (1992).</p> <p>* Daw, et al., "Glutamic Acid Decarboxylase Autoantibodies in Stiff-Man Syndrome and Insulin-Dependent Diabetes Mellitus Exhibit Similarities and Differences in Epitope Recognition", <i>J. Immunol.</i> 156 (2): 818-825 (1996).</p> <p>* De Caestecker, M.P., et al., "The Detection Of Intercytoplasmic Interleukin 1 (Alpha) Expression In Human Monocytes Using Two Colour Immunofluorescence Flow Cytometry", <i>J. Immunol. Methods</i> 154:11-20 (1992).</p> <p>* Demuth, H.U., et al. "Design Of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides As Potent Inhibitors Of Proline-Specific Peptidases", <i>FEBS Lett.</i>, 320:23-27, (1993).</p> <p>* Dudler, et al., "Carbohydrate-Dependent, HLA Class II-Restricted, Human T Cell Response to the Bee Venom Allergen Phospholipase A2 in Allergic Patients", <i>Eur. J. Immunol.</i> 25 (2):538-542 (1995).</p> <p>* Duke-Cohan, J.S., et al., "Targeting Of An Activated T-Cell Subset Using A Bispecific Antibody-Toxin Conjugated Directed Against CD4 AND CD26", <i>Blood</i>, 82:2224-2234, (1993).</p>			

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin		
		Filing Date: April 9, 1999	Group: 1653	
<p>Dupont, B., "Immunology Of Hematopoietic Stem Cell Transplantation: A Brief Review Of Its History", <i>Immun. Rev.</i>, 157:5-12, (1997)</p> <p>* Ebenichler, C., et al., "Structure-function Relationships Of The HIV-1 Envelope V3 Loop Tropism Determinant: Evidence For Two Distinct Conformations", <i>Aids</i> 7:639-646 (1993).</p> <p>* El Far, et al., "Antigens Associated with N- and L-Type Calcium Channels in Lambert - Eaton Myasthenic Syndrome", <i>J. Neurochemistry</i>, 64 (4): 1696-1702 (1995).</p> <p>* Fauci, A.S., "The Human Immunodeficiency Virus: Infectivity And Mechanisms Of Pathogenesis", <i>Science</i>, 239:617:722 (1988).</p> <p>* Fleisher, B., et al., "Triggering of Cytotoxic T Lymphocytes and NK Cells Via The Tp 103 Pathway is Dependent On the Expression Of The T Cell Receptor/CD3 Complex", <i>J. Immuno.</i>, 141:1103-1107.</p> <p>* Flentke, G.R., et al., "Inhibition Of Dipeptidyl Aminopeptidase IV (DP-IV) By XAA-Boropro Diptides And Use Of These Inhibitors To Examine The Role Of DP-IV IN T-Cell Function", <i>Proc. Natl. Acad. Sci. USA</i>, 88:1556-1559, (1991)</p> <p>* Freeman, et al., "T and B Cell Reactivity to Adrenal Antigens in Autoimmune Addison's Disease" <i>Clinical & Experimental Immunology</i> 88 (2): 275-279 (1992)</p> <p>Goodman, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls", <i>Annals Of The Rheumatic Diseases</i>, 55: 40-46, 1996.</p> <p>* Goodman, M., and Chorev, M., "On The Concept Of Linear Modified Retro-Peptide Structures", <i>Accounts of Chemical Research</i>, 12:1-7 (1979)</p> <p>Goodstone, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls" <i>Annals Of The Rheumatic Diseases</i> 55(1):40-46 (1996).</p> <p>* Guichard, G., et al. "Partially Modified Retro-Inverso Pseudopeptides As Non-Natural Ligands For The Human Class I Histocompatibility Molecule HLA-A2", <i>J. Med. Chem.</i>, 39:2030-2039, (1996)</p> <p>* Günther, U.L., et al., "Solution Structures Of The DP IV (CD26) Inhibitor Val-BoroPro Determined By NMR Spectroscopy", <i>Magnetic Resonance in Chem.</i>, 33:959-970, (1995)</p> <p>Gutheil, W.G., et al., "Separation Of L-PRO-DL-Boropro Into Its Component Diastereomers And Kinetic Analysis Of Their Inhibition Of Dipeptidyl Peptidase IV. A New Method For The Analysis Of Slow, Tight-Binding Inhibition", <i>Biochemistry</i>, 32:8723-8731, (1993)</p> <p>* Hall, et al., "Immunogenetics of Dermatitis Herpetiformis", <i>Seminars in Dermatology</i>, 10(3):240-245 (1991).</p> <p>* Hart, et al., "Design of Experimental Synthetic Peptide Immunogens for Prevention of HIV-1 and HTLV-1 Retroviral Infections", <i>Pharmaceutical Biotechnology</i> 6:821-845 (1995).</p> <p>* Hegen, M., et al. "Enzymatic Activity Of CD26 (Dipeptidylpeptidase IV) Is Not Required For Its Signalling Function In T Cells", <i>Immunobiology</i>, 189:483-493, (1993)</p> <p>* Hegen, M., et al. "Function Of Dipeptidylpeptidase IV (CD26, TP103) In Transfected Human T Cells", <i>Cell Immunol.</i>, 146:249-260, (1993)</p>				

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin		
		Filing Date: April 9, 1999	Group: 1653	
<p>* Hegen, M., et al., "The T Cell Triggering Molecule Tp 103, <i>J. Immunol.</i>, 144:2980-2914 (1990).</p> <p>* Heins, J., et al., "Mechanism of Proline-Specific Proteinases: (I) Substrate Specificity of Dipeptidyl Peptidase Peptidase IV From Pig Kidney and Proline-Specific Endopeptidase From <i>Flavobacterium Meningosepticum</i>", <i>Biochimica Biophysica Acta</i>, 954:161-169 (1988).</p> <p>* Ikagawa, et al., "Single Amino and Acid Substitutions on a Japanese Cedar Pollen Allergen Cry J-1) Derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism" <i>J. Allergy & Clinical Immunol.</i> 97 (1 Pt 1): 53-64 (1996).</p> <p>* James, et al., "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C" <i>Clinical & Experimental Rheumatology</i>, 13 (3):299-305 (1995).</p> <p>* Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", <i>Nature</i>, 368:744-746, (1994).</p> <p>* Janeway, C., et al., "Immunobiology - The Immune System In Health And Disease", <i>Current Biology LTD</i>, Chapter 12, pp. 1-35, (1994).</p> <p>* Jardetzky, T.S., et al., "Three-Dimensional Structure Of A Human Class II Histocompatibility Molecule Complexed With Superantigen", <i>Nature</i>, 368:711-718 (1994).</p> <p>* Jiang, et al., "Inhibition of Human Immunodeficiency Virus Type I Infection in a T-Cell Line (CEM) by New Dipeptidyl-Peptidase IV (CD26) Inhibitors", <i>Res Viral</i>, 148: 255-266, 1997.</p> <p>* Jorgensen, J.L., et al., "Molecular Components Of T-Cell Recognition," <i>Annu. Rev. Immunol.</i> 10:835-873 (1992).</p> <p>* Kalluri, et al., "Identification of the Alpha 3 Chain of Type IV Collagen as the Common Autoantigen in Antibasement Membrane Disease and Goodpasture Syndrome", <i>J. The American Society Of Nephrology</i> 6 (4):1178-1185 (1995).</p> <p>* Kameoka, J., et al., "Direct Association Of Adenosine Deaminase With A T Cell Activation Antigen, CD26", <i>Science</i>, 261:466-469, (1993).</p> <p>* Kameoka, Jr., et al., "Differential CD26-Mediated Activation Of The CD3 AND CD2 Pathways After CD6-Depleted Allogeneic Bone Marrow Transplantation", <i>Blood</i> 85:1132-1137, (1995).</p> <p>* Karges, et al., "Self and Non-Self Antigen in Diabetic Autoimmunity: Molecules and Mechanisms", <i>Molecular Aspects Of Medicine</i> 16(2):29-213 (1995).</p> <p>* Kelly, T.A., et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation Between Conformation And Activity", <i>J. Am. Chem. Soc.</i>, 115:12637-12638, (1993).</p> <p>* Kelly, T.A., et al., "The Efficient Synthesis And Simple Resolution Of A Proline Boronate Ester Suitable For Enzyme Inhibition Studies", <i>Tetrahedron</i> 49:1009-1016 (1993).</p> <p>* Kettner, C.A. and Shenvi, A.B., "Peptide Boronic Acid Inhibitors Of Trypsin-Like Proteases Their Preparation And Use As Anticoagulants And Inflammation Inhibitors", <i>Chemical Abstracts</i>, (1990), 112:80 (91790c).</p> <p>* Kettner, C.A., et al., "Kinetic Properties Of The Binding Of Alpha-Lytic Protease To Peptide Boronic Acids", <i>Biochemistry</i>, 27:7682-7688, (1988).</p>				

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin	
		Filing Date: April 9, 1999	Group: 1653
<p>* Kinder, D., et al., "Analogues of Carbamyl Aspartate as Inhibitors..." <i>J. Med. Chem.</i>, 33:819-823 (1990).</p> <p>* Kokowa, et al., "Detection of Platelet Antigen for Antiplatelet Antibodies in Idiopathic Thrombocytopenic Purpura by Flow Cytometry, Antigen-Capture ELISA, and Immunoblotting: A Comparative Study", <i>Eur. J. Hematology</i> 50 (2): 74-80 (1993).</p> <p>* Kubota, T., et al., "Dipeptidyl Peptidase IV (DP IV) Activity In Serum and On Lymphocytes Of Mrl/Mpr/lpr/lpr Mice Correlates With Disease Onset", <i>Clin. Exp. Immunol.</i>, 96:292-296. (1994).</p> <p>* Kubota, T., et al., "Involvement Of Dipeptidyl Peptidase IV In An In Vivo Immune Response", <i>Clin. Exp. Immunol.</i>, 89:192-197, (1992).</p> <p>* Kuchroo, V.K., et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated By A Diverse T Cell Repertoire", <i>J. Immunol.</i> 153:3326-3336 (1994).</p> <p>* Kuchroo, V.K., et al., "Cytokines And Adhesion Molecules Contribute To The Ability of Myelin Proteolipid Protein-Specific T Cell Clones To Mediate Experimental Allergic Encephalomyelitis", <i>J. Immunol.</i> 151:4371-4382 (1993).</p> <p>* Kuchroo, V.K., et al., "Experimental Allergic Encephalomyelitis Medicated By Cloned T Cells Specific For A Synthetic Peptide of Myelin Proteolipid Protein. Fine Specificity And T Cell Receptor V Beta Usage", <i>J. Immunol.</i> 148:3776-3782 (1992).</p> <p>* Kuchroo, V.K., et al., "Induction Of Experimental Allergic Encephalomyelitis By Myelin Proteolipid-Protein-Specific T Cell Clones and Synthetic Peptides", <i>Pathobiology</i> 59:305-312 (1991).</p> <p>* Kuchroo, V.K., et al., "T Cell Receptor (TCR) Usage Determines Disease Susceptibility In Experimental Autoimmune Encephalomyelitis: Studies with TCR V Beta * .2 Transgenic Mice", <i>J. Experimental Medicine</i> 179:1659-1664 (1994).</p> <p>* Kuchroo, V.K., et al., "T-cell Receptor Alpha Chain Plays a Critical Role in Antigen-Specific Suppressor Cell Function", <i>Proc. Natl. Acad. Sci. USA</i> 88:8700-8704 (1991).</p> <p>* Linington, et al., "Cell Adhesion Molecules of the Immunoglobulin Supergene Family as Tissue-Specific Autoantigens: Induction of Experimental Allergic Meritis (EAN) by PO Protein-Specific T Cell Lines", <i>Eur. J. Immunol.</i> 22 (7): 1813-1817 (1992).</p> <p>* Linsley, P.S., et al., "Effects of Anti-gp 120 Monoclonal Antibodies On CD4 Receptor Binding By The Env Protein Of Human Immunodeficiency Virus Type 1", <i>J. Virology</i> 62:3695-3702 (1988).</p> <p>* Liu, et al., "Molecular Mapping of a Pathogenically Relevant BP180 Epitope Associated with Experimentally Induced Murine Bullous Pemphigoid" <i>J. Immunol.</i> 155 (11): 5449-5454 (1995).</p> <p>* Lopez, et al., "Characterization of SPf(66)n: A Chimeric Molecule Used as a Malaria Vaccine" <i>Vaccine</i>, 12 (7):585-591 (1994).</p> <p>Lustig, et al., "Update on Viral Pathogenesis", Recent Work on Three Human Pathogens Illustrates the Paths Being Taken in Viral Pathogenesis Research" <i>ASM News</i>, 56(7): 366-368, 1990.</p>			

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin		
		Filing Date: April 9, 1999	Group: 1653	
<ul style="list-style-type: none"> * Marguett, et al., "cDNA Cloning for Mouse Thymocyte-Activating Molecule", A Multifunctional Ecto-Dipeptidyl Peptidase IV (CD26) Included in a Subgroup of Serine Proteases", <i>The Journal of Biological Chemistry</i>, 267(4): 2200-2208, 1992. * Matteson, D., et al., "Synthesis And Properties Of Pinanediol a-Amino Boronic Esters" <i>Organometallics</i>, 3:1284-1288, (1984). * Mittrucker, H.W., et al. "The Cytoplasmic Tail Of The T Cell Receptor Zeta Chain Is Required For Signaling Via CD26", <i>Eur J. Immunol.</i>, 25:295-297. (1995) * Morimoto, C., et al, 1F7 "A Novel Cell Surface Molecule, Involved in Helper Function Of CD4 cells". <i>J. Immunol.</i>, 143:34030-3439 (1989) and published erratum appears in <i>J. Immunology</i> 144 (5):2027 (1990). * Mosmann, T.R., "Cytokine Patterns During The Progression To Aids", <i>Science</i>, 265:193-194, (1994). * Mullins, et al., "Transgenesis in the Rat and Larger Mammals" <i>J. Clinical Investigation</i> 96 (1): 30-37 (1996). * Nardelli, et al., "A Chemically Defined Synthetic Vaccine Model for HIV-1", <i>J. Immunol.</i> 148 (3): 914-920 (1992). * Nicola, N., et al., "Guidebook To Cytokines And Their Receptors", <i>Sambrook and Tooze Publication</i>, Pp. 1-257, (1994). * O'Brien, et al., "An Immunogenetic Analysis of the T-Cell Recognition of the Major House Dust Mite Allergen Der p2: Identification of High- and Low-Responder HLA-DQ Alleles and Localization of T-Cell Epitopes" <i>Immunology</i> 86 (2):176-182 (1995). * Paolina-Bordignon, F., et al., "Universally Immunogenic T Cell Epitopes: Promiscuous Binding To Human MHC MHC Class II And Promiscuous Recognition By T Cells", <i>Eur. J. Immunol.</i> 19:2237-2242 (1989). * Ostresh, et al., "Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries", <i>Methods in Enzymology</i>, 267: 220-234, 1996 * Perry, et al., "Autoreactive T Cell Specificity in Autoimmune Hemolytic Anemia of the NZB Mouse", <i>Eur. J. Immunol.</i> 26(1): 136-141 (1996). * Perseon Biotech Company, "Molecular Biology Catalog", (1994) * Powers, C., et al., "Elastase Inhibitors For Treatment Of Emphysema - NHLBI Workshop Summary" <i>US Dept. of Health and Human Services</i>, 1097-1100, (1985). * Protti, et al., "Myasthenia Gravis: Recognition of a Human Autoantigen at the MolecularLevel" <i>Immunol. Today</i> 14 (7):363-368 (1993). Reinhold, D., et al., "Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-1 (TGF-1) in stimulated mouse splenocytes and thymocytes" <i>Immunology Letters</i> , 58:29-35, (1997). * Reynolds, et al., "T and B Epitope Determination and Analysis of Multiple Antigenic Peptides for the Schistosoma mansoni Experimental Vaccine Triose-Phosphate Isomerase", <i>J. Immunol.</i>152 (1):193-200 (1994). 				

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin		
		Filing Date: April 9, 1999	Group: 1653	
<p>* Rini, J.M., et al., "Crystal Structure Of A Human Immunodeficiency Virus Type 1 Neutralizing Antibody, 50.1, In Complex With Its V3 Loop Peptide Antigen", <i>Proc. Natl. Acad. Sci. USA</i> 90:6325-9 (1993).</p> <p>* Ritu, et al., "Construction of Synthetic Immunogens: Use of T- and B-Cell Epitopes of CS and RESA Proteins of Plasmodium falciparum" <i>Vaccine</i> 10 (11): 761-765 (1992).</p> <p>* Scharpe, S., et al., "Purified And Cell-Bound CD26: Enzymatic Inhibition, Antibody Binding Profile, And Expression On T Cells In Relation To Other Surface Markers", <i>Verh. K. Acad. Geneeskd. Belg.</i> 56:537-559. (1994)</p> <p>Schmitz T., et al., "Potentiation Of The Immune Response In Hiv-1 + Individuals", <i>J. Clin. Invest.</i>, 97:1545-1549, (1996).</p> <p>* Schon, E., et al., "Dipeptidyl Peptidase IV in Human T Lymphocytes. An Approach To The Role Of A Membrane Peptidase In The Immune System", <i>Biomedica Biochimica Acta</i>, 45:1523-1528 (1986).</p> <p>* Schon, E., et al., "Dipeptidyl Peptidase IV In The Immune System", <i>Biol. Chem. Hoppe-Seyler</i>, 372:305-311, (1991).</p> <p>* SchöN, E., et al., "Dipeptidyl Peptidase IV In The Immune System. Effects of Specific Enzyme Inhibitors On The Activity Of Dipeptidyl Peptidase IV And Proliferation Of Human Lymphocytes", <i>Biological Chemistry Hoppe Seyler</i> 372:305-311 (1991).</p> <p>* Schon, E., et al., "The Dipeptidyl Peptidase IV, A Membrane Enzyme Involved In The Proliferation Lymphocytes", <i>Biomedica Biochimica Acta</i>, 44 (1985).</p> <p>* SchöN, E., et al., "The Role Of Dipeptidyl Peptidase IV In Human T Lymphocyte Activation. Inhibitors And Antibodies Against Dipeptidyl Peptidase IV Suppress Lymphocyte Proliferation And Immunoglobulin Synthesis In Vitro", <i>Eur. J. Immunol.</i> 17:1821-1826 (1987).</p> <p>* Seed, B., "Making Agonists Of Antagonists", <i>Chemistry & Biology</i>, 1:125-129 (1994).</p> <p>* Shimjo, et al., "Identification of the Disease-Related T Cell Epitope of Ovalbumin and Epitope Targeted T Cell Inactivation in Egg Allergy" <i>Int'l. Archives of Allergy & Immunol.</i> 105 (2):155-161 (1994).</p> <p>* Snow, R.J., et al., "Studies On Proline Boronic Acid Dipeptide Inhibitors Of Dipeptidyl Peptidase IV: Identification Of A Cyclic Species Containing A B-N Bond", <i>J. Am. Chem. Soc.</i>, 116:10860-10869, (1994).</p> <p>* Songyang, Z., et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences", <i>Cell</i>, 72:767-778, (1993).</p> <p>* Subramanyam, M., et al., "CD26, AT-Cell Accessory Molecule Induction Of Antigen-Specific Immune-Suppression By Inactivation OF CD26: A Clue To The Aids Paradox?", in <i>Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response</i>, Ed. B. Fleischer. 155-162, (1995)</p> <p>* Subramanyam, M., et al., "Mechanism Of Hiv-1 Tat Induced Inhibition Of Antigen-Specific T Cell Responsiveness", <i>J. Immunol.</i> 150:2544-2553, (1993)</p> <p>Subramanyam, W.G., et al., "Mechanism of HIV-1 Tat Induced Inhibition Of Antigen-Specific T Cell Responsiveness", <i>J. Immunol.</i> 150:2544-2553 (1993).</p>				

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
		Applicant: Bachovchin	
		Filing Date: April 9, 1999	Group: 1653
<p>* Sudmeier, J.L., et al., "Solution Structures Of Active And Inactive Forms Of The DP IV (CD26) Inhibitor Pro-Boropro Determined By Nmr Spectroscopy", <i>Biochemistry</i>, 33:12427-12438, (1994).</p> <p>* Tam, J.P., "Synthetic Peptide Vaccine Design: Synthesis And Properties Of A High-Density Multiple Antigenic Peptide System", <i>Proc. Natl. Acad. Sci. USA</i>, 85:5409-5413, (1988).</p> <p>* Tanaka, T., et al. "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", <i>J. Immunol.</i>, 149:481-486, (1992).</p> <p>* Tanaka, T., et al., "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", <i>J. Immunol.</i> 149: 481-486 (1992); published erratum appears in <i>J. Immunol.</i> 50(5):2090 (1993).</p> <p>* Tanaka, T., et al., "The Costimulatory Activity Of The CD26 Antigen Requires Dipeptidyl Peptidase IV Enzymatic Activity", <i>Proc. Natl. Acad. Sci. USA</i>, 90:4586-4590, (1993).</p> <p>* Thompson, R., "Use Of Peptide Aldehydes To Generate Transition-State Analogs Of Elastase", <i>Biochemistry</i>, 12:147-51 (1973).</p> <p>Thompson, R. "Peptide Aldehydes: Potent Inhibitors of Serine and Cysteine Proteases", 19: 220-225.</p> <p>* Uibo, et al., "Characterization of Adrenal Autoantigens Recognized by Sera From Patients with Autoimmune Polyglandular Syndrome (APS) Type I. (<i>J. Autoimmunity</i> 7 (3): 399-411 (1994).</p> <p>* Van Noort, et al., "The Small Heat-Shock Protein Alpha B-Crystallin as Candidate Autoantigen in Multiple Sclerosis" <i>Nature</i> 375 (6534):798-801 (, 2995).</p> <p>* Watson, J.D., "Continuous Proliferation Of Murine Antigen Specific Helper T Lymphocytes in Culture", <i>J. Experimental Medicine</i> 150:1510 (1979).</p> <p>* Welch, J.T., and Lin J., "Fluoroleucin Containing Dipeptide Isoteres As Inhibitors Of Dipeptidyl Peptidase IV (CD26)", <i>Tetrahedron</i>, 52:291-304, (1995).</p> <p>* Wijdenes, et al., "Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which Use the gp130 For Signal Transduction", Abstract.</p> <p>* Wyss-Coray, T., et al., "Use Of Antibody/Peptides Constructs Of Direct Antigenic Peptides To T Cells: Evidence For T Cells Processing And Presentation", <i>Cellular Immunol.</i>, 139 (1):268-73 (1992).</p> <p>* Yoshimoto, T., et al., "Comparison Of Inhibitory Effects Of Prolinal-Containing peptide Derivates On Prolyl...", (1985) <i>J. Biochem.</i>, 98:975-979, (1985)</p> <p>* Zhu, X., et al., "T Cell Epitope Mapping of Ragweed Pollen Allergen Ambrosia Artemisiifolia (Amb a 5) and Ambrosia Trifida (Amb t 5) and the Role of Free Sulphydryl Groups in T Cell Recognition" <i>J. Immunol.</i> 155 (10):5064-5073 (1995).</p> <p>* Zimmerman, D.H., et al. "A New Approach To T-Cell Activation: Natural And Synthetic Conjugates Capable Of Activating T Cells", <i>Vaccine Res.</i>, 5:91-102, (1996).</p> <p>Zimmerman, D.H., et al., "Immunization With Peptide Heteroconjugates Primes A T Helper Cell..." <i>Vaccine Res.</i> 5:103-118, (1996).</p>			

OCT. 17. 2003 2:04PM CHOATE HALL & STEWART 6172484000

NO. 858 P. 13

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Bachovchin	
		Filing Date: April 9, 1999	Group: 1653
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

318439_1.DOC